Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dark

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials groupGraham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials groupGraham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Pageof 3